OMB
.report
Search
Focus Groups to assess the post-marketing safety of authorized generic drug products
Focus Groups About Drug Products As Used by The Food and Drug Administration
OMB: 0910-0677
IC ID: 221655
OMB.report
HHS/FDA
OMB 0910-0677
ICR 201604-0910-008
IC 221655
( )
⚠️ Notice: This information collection may be referencing outdated material. More recent filings for OMB 0910-0677 can be found here:
2020-01-10 - Extension without change of a currently approved collection
2017-03-15 - Extension without change of a currently approved collection
Documents and Forms
Document Name
Document Type
Appendix A - Recruitment mailer_3_14_2016.pdf
Other-Study recruitment mailer
Appendix B - Screening_guides_3_30_2016.pdf
Other-Study Screening Guide
Appendix C - Focus group guide_4-8-2016.pdf
Other-Focus group guide
Focus Groups About Drug Products.pdf
OMB Request for Generic Allotment Memo
IC Document
OMB-FDA Q&A June 2016.docx
FDA-OMB Q&A June 2016
IC Document
Information Collection (IC) Details
View Information Collection (IC)
IC Title:
Focus Groups to assess the post-marketing safety of authorized generic drug products
Agency IC Tracking Number:
CDER
IC Status:
New
Obligation to Respond:
Voluntary
CFR Citation:
Information Collection Instruments:
Document Type
Form No.
Form Name
Instrument File
URL
Available Electronically?
Can Be Submitted Electronically?
Electronic Capability
Other-Study recruitment mailer
Appendix A - Recruitment mailer_3_14_2016.pdf
No
Paper Only
Other-Study Screening Guide
Appendix B - Screening_guides_3_30_2016.pdf
No
Paper Only
Other-Focus group guide
Appendix C - Focus group guide_4-8-2016.pdf
No
Paper Only
Federal Enterprise Architecture Business Reference Module
Line of Business:
Health
Subfunction:
Consumer Health and Safety
Privacy Act System of Records
Title:
FR Citation:
Number of Respondents:
32
Number of Respondents for Small Entity:
0
Affected Public:
Individuals or Households
Percentage of Respondents Reporting Electronically:
0 %
Approved
Program Change Due to New Statute
Program Change Due to Agency Discretion
Change Due to Adjustment in Agency Estimate
Change Due to Potential Violation of the PRA
Previously Approved
Annual Number of Responses for this IC
32
0
32
0
0
0
Annual IC Time Burden (Hours)
64
0
64
0
0
0
Annual IC Cost Burden (Dollars)
0
0
0
0
0
0
Documents for IC
Title
Document
Date Uploaded
OMB Request for Generic Allotment Memo
Focus Groups About Drug Products.pdf
05/23/2016
FDA-OMB Q&A June 2016
OMB-FDA Q&A June 2016.docx
08/10/2016
Blank fields in records indicate information that was not collected or not collected electronically prior to July 2006.